Table 4.
Adverse events in colistin and ceftolozane/tazobactam treated patient groups.
| Most frequent adverse events | CMS group (n = 33) | C/T group (n = 18) | p value |
|---|---|---|---|
| Clostridioides difficile colitis | 3 (9.1%) | 0 (0%) | 0.54a |
| Diarrhoea | 7 (21.2%) | 2 (11.1%) | 0.46a |
| Vomiting | 10 (30.3%) | 2 (11.1%) | 0.17a |
| Atrial fibrillation | 8 (24.2%) | 3 (16.7%) | 0.72a |
| Erythema | 5 (15.2%) | 1 (5.5%) | 0.40a |
| Kidney injury | 16 (48.5%) | 2 (11.1%) | 0.01a* |
| Liver function abnormalities | |||
| Increased aspartate aminotransferase | 6 (18.2%) | 4 (22.2%) | 0.72a |
| Increased alanine aminotransferase | 8 (24.2%) | 5 (27.8%) | 1.00a |
| Increased γ-glutamyl-transferase | 11 (33.3%) | 3 (16.7%) | 0.32a |
| Increased alkaline phosphatase | 8 (24.2%) | 1 (5.5%) | 0.13a |
Data are expressed as absolute numbers (percentage).
CMS colistimethate sodium; C/T ceftolozane/tazobactam.
aχ2 test or Fisher’s exact test.
*p < 0.05.